Company intelligence / Profile preview

Trillium Therapeutics Inc.

Mississauga, Ontario, Canadaorpha.net ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Trillium's lead molecules TTI-622 and TTI-621 showed promising clinical activity in Phase 1 trials for relapsed/refractory lymphomas, with TTI-622 demonstrating a 33% overall response rate at doses of 0.8-18 mg/kg and TTI-621 showing 18-29% overall response rate at up to 2.0 mg/kg. Deep and durable responses were observed in heavily pretreated patients with advanced DLBCL[9].

Therapeutic areas: Oncology
Modalities: BiologicsSIRPα-Fc fusion proteinssmall molecule STING agonists
Industry: Biotech

Drug pipeline

3 assets

ontorpacept

Phase 2

Indications: Large B-cell lymphoma, Breast cancer

2 more assets in the full pipeline.

Request access →

Partnerships

Pfizer (initially invested $25 million in September 2020 before acquisition)

Beyond the preview

Go deeper on Trillium Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trillium Therapeutics Inc..

Explore the full profile